tm logo
MYOPEPDYS (VESLETEPLIRSEN) INJECTION
Live/Pending
NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER

record initialized not assigned to examiner

on 23 Jan 2024

Last Applicant/ Owned by

215 First Street

Cambridge

MA

02142

Serial Number

98370905 filed on 23rd Jan 2024

Registration Number

N/A

Correspondent Address

Maury M. Tepper, III Tepper & Eyster, PLLC

3724 Benson Drive

Raleigh, NC 27609

UNITED STATES

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

MYOPEPDYS (VESLETEPLIRSEN) INJECTION

Medical services; providing health information Color is not claimed as a feature of the mark. Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular dise Read More

Classification Information


Class [044]
Medical, Beauty & Agricultural Services


Medical services; providing health information


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Class [041]
Education and Entertainment Services


Medical training and teaching


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases


First Use Date in General

11th 000101

First Use Date in Commerce

11th 000101

Mark Details


Serial Number

No 98370905

Mark Type

No Service Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Design Code(s)

26.15.03 -

Incomplete polygons and polygons made of broken or dotted lines

Description of Design Search

The mark consists of two stylized open-shaped polygons, slightly juxtaposed and facing one another that together form a stylized hexagon; the polygon on the left faces to the upper right and consists of five segments and the polygon on the right faces to the lower left and consists of four segment. The word MYOPEPDYS is to the right of the polygons and the term '(vesleteplirsen) injection' is below MYOPEPDYS. Color is not claimed as a feature of the mark.

Legal History


Status DateAction Taken
28th May 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28th May 2024NOTICE OF DESIGN SEARCH CODE E-MAILED
23rd Jan 2024NEW APPLICATION ENTERED